Results-Unaudited Financial Statements For The Quarter And Half Year Ended 30th September 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The company reported unaudited Q2 FY26 revenue of ₹6,562.38 lacs (vs ₹2,455 lacs in Q2 FY25) and H1 FY26 revenue of ₹36,553.83 lacs. Profit after tax for Q2 was ₹850.47 lacs (vs ₹183.83 lacs) and H1 PAT was ₹3,180.41 lacs. However, the statutory auditor issued a Disclaimer of Opinion stating they could not verify sales, purchases, inventory valuation, trade receivables, unsecured loans (no agreements), and that no Fixed Assets register was provided. The entire reported business has shifted to a new 'Agriculture' segment, with the previously dominant Drugs & Pharmaceutical segment showing zero revenue. Management blamed the audit issues on lack of records from the previous management.
Despite the strong reported numbers, the auditor's disclaimer means the financial statements are unreliable and the figures cannot be relied upon. Shareholders should treat the headline growth with extreme caution as the books may be materially misstated, and this is a significant red flag for the stock.